{
    "medicine_id": "520b4a144a826f613b2e39322703b622941dc694",
    "platform_id": "DB15696",
    "metadata": {
        "name": "Pfizer BioNTech Covid 19 Vaccine 0 23 mg 1 8mL Injection suspension",
        "composition": "0 23 mg 1 8mL Pfizer BioNTech Covid 19 Vaccine",
        "clinical_particulars": {
            "therapeutic_indications": "Tozinameran has not yet been fully approved by any country In both the UK and Canada Tozinameran is indicated under an interim authorization for active immunization to prevent COVID 19 caused by SARS CoV 2 in individuals aged 16 years and older L26671 L26676 On December 11 2020 the U S Food and Drug Administration granted emergency use authorization EUA for Tozinameran to prevent COVID 19 caused by severe acute respiratory syndrome coronavirus 2 SARS CoV 2 in patients aged 16 years and above L26956 Safety and immune response information for adolescents 12 15 years of age will follow and studies to further explore the administration of Tozinameran in pregnant women children under 12 years of age and those in special risk groups will be evaluated in the future A225386 This vaccine should only be administered where appropriate medical treatment for immediate allergic reactions are immediately available in the case of an acute anaphylactic reaction after vaccine administration L26996 Tozinameran administration should be postponed in any individual suffering from an acute febrile illness Its use should be carefully considered in immunocompromised individuals and individuals with a bleeding disorder or on anticoagulant therapy Appropriate medical treatment should be readily available in case of an anaphylactic reaction following vaccine administration L26671 L26676",
            "contraindications": {
                "disease": "Toxicity information regarding Tozinameran is not readily available Patients experiencing an overdose are at an increased risk of severe adverse effects such as injection site reactions headache arthralgia myalgia fatigue chills and pyrexia L26671 L26676 Symptomatic and supportive measures are recommended",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Tozinameran is a nucleoside modified mRNA modRNA vaccine encoding an optimized full length version of the SARS CoV 2 spike S protein translated and expressed in cells in vaccinated individuals to produce the S protein antigen against which an immune response is mounted As with all vaccines protection cannot be guaranteed in all recipients and full protection may not occur until at least seven days following the second dose L26671 L26676 In U S clinical trials the vaccine was 95 effective in preventing COVID 19 eight COVID 19 cases occurred in the vaccine group and 162 cases occurred in the placebo group Of the total 170 COVID 19 cases one case in the vaccine group and three cases in the placebo group were considered to be severe infections A225386 L26956",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}